Immunosuppressed individuals are at high risk for the development of hematologic malignancies. The typical lymphomas arising in organ transplant recipients are B-cell non-Hodgkin's lymphomas that contain Epstein-Barr virus (EBV) DNA sequences. We investigated the characteristics of posttransplant lymphomas that lacked expression of the usual markers associated with EBV transformation. We describe four large-cell lymphomas seen recently at our institution. Two of these four cases were CD4+, one was CD8+. and in one staining for CD4 and CD8 expression was not performed. One CD4+ lymphoma was a CD30+, EBV-large-cell lymphoma from a 65-year-old kidney transplant recipient, the second was an EBV+ large-cell lymphoma from a 25-year-old heart transplant patient. Two T-cell lymphomas were EBV+ and had clonal T-cell receptor @ gene rearrangements. The other t w o lym-HE RELATIONSHIP between an individual's propen-
Immunosuppressed individuals are at high risk for the development of hematologic malignancies. The typical lymphomas arising in organ transplant recipients are B-cell non-Hodgkin's lymphomas that contain Epstein-Barr virus (EBV) DNA sequences. We investigated the characteristics of posttransplant lymphomas that lacked expression of the usual markers associated with EBV transformation. We describe four large-cell lymphomas seen recently at our institution. Two of these four cases were CD4+, one was CD8+. and in one staining for CD4 and CD8 expression was not performed. One CD4+ lymphoma was a CD30+, EBV-large-cell lymphoma from a 65-year-old kidney transplant recipient, the second was an EBV+ large-cell lymphoma from a 25-year-old heart transplant patient. Two T-cell lymphomas were EBV+ and had clonal T-cell receptor @ gene rearrangements. The other t w o lym-HE RELATIONSHIP between an individual's propen-T sity to develop a malignancy and the state of his or her immune system is clearly shown in the increased incidence of lymphomas observed among immunosuppressed patient~.'.~ Patients with inherited deficiencies of T-or B-cell immunity experience a 100-fold increase in their incidence of cancer, with non-Hodgkin's lymphoma (NHL) being the most common malignancy (49% of cases) and intermediategrade NHL (diffuse large cell) and high-grade NHL (immunoblastic) the most common histologic subtypes of NHL s e e n . '~~,~ Patients with the acquired immunodeficiency syndrome (AIDS) have a greatly increased risk of developing intermediate-or high-grade NHL.6 Approximately one-third of the AIDS-related lymphomas contain the EBV genome, the presence of which is preferentially associated with an immunoblastic-plasmacytoid histol~g y . ' -'~ Patients that have received solid organ transplants experience a 45-to 100-fold increase in the incidence of NHL; their risk of developing lymphoma is related to the degree and duration of their immunos~ppression."-'~ The tumors that develop in transplant patients are generally monoclonal and oligoclonal B-cell lymphomas that contain EBV DNA in the great majority of c a~e s . '~-'~ We have previously reported the growth of primary T-cell NHL as clonal tumors in severe combined immunodeficient (SCID) mice and SCID mice containing human lymphoid xenografts (SCID-hu mice).20 Others have reported that EBV-transformed lymphoblastoid cells grow as oligoclonal tumors in SCID m i~e .~' -'~ We were interested in identifying cases of T-cell posttransplant lymphoma and determining whether SCID and SCID-hu mice would support the growth of primary NHL that arose in immunocompromised patients. One problem in using SCID and SCID-hu mice to study the in vivo growth of primary NHL has been the outgrowth of EBV-transformed lymphoblastoid B cells that are admixed with the clonal tumor population in primary tumor tissue.20 The tumors that result from the growth of these contaminating lymphoblastoid cells are similar, by immunohistologic and genotypic analyses, to the phomas expressed T-cell markers CD4 and CD43, and lacked expression of B-cell markers CDI 9, CD20, CD21, CD22, CD23, and surface lg. Both CD4+ lymphomas were tumorigenic after their heterotransplantation into severe combined immunodeficient (SCID) mice. Cytogenetics, immunophenotyping, and genotyping of the secondary tumors from SCID mice showed their clonality and identity with the patients' primary tumors. Novel CD4+ lymphoma cell lines, LH521/4 and LK418/4, were established from tumors that had been passaged in SCID mice. An immunodeficient environment may facilitate the growth of these T-cell or biphenotypic lymphomas; the etiology of their genesis can include transformation with EBV and other, as yet unidentified mechanisms. B-cell lymphoblastoid tumors that arise in SCID mice engrafted with peripheral blood lymphocytes (PBL) from EBV-seropositive patients." It would have been of great interest if agents other than EBV might result in the transformation of lymphoid cells in the posttransplant setting, and if the properties of these lymphomas would differ from those of EBV-transformed lymphoblastoid cells, thereby simplifying the identification of tumors in SCID mice that result from the transplantation of primary posttransplant lymphomas. We have previously described eight cases of posttransplant lymphoma and lymphoproliferative disorder that developed during the period of January 1977 through June 1983, during which genotyping showed the presence of EBV DNA sequences and clonal Ig gene rearrangements in each case.I5 In a review of 19 cases of posttransplant lymphoma and lymphoproliferative disorders seen at Stanford University Medical Center and the Palo Alto Veterans Hospital in the period of June 1983 through December 1992, we found 4 cases of lymphoma and 1 case of a lymphoproliferative disorder that were notable for their expression of T-cell-associated surface markers and the absence of markers usually associated with EBV-transformed,
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WALLER ET AL lymphoblastoid tumors. Frozen cell suspensions suitable for transplantation were available from 2 of the 4 lymphoma cases; heterotransplantation of these two cases of primary posttransplant lymphoma into SCID and SCID-hu mice resulted in the growth of clonal tumors with identical immunophenotypes and genotypes as the primary tumors. We present below the case histories of the four patients whose lymphomas expressed T-cell surface markers, and a characterization of the immunophenotype, genotype, and cytogenetics of their lymphomas. The pattern of growth of the two CD4' lymphomas that grew after heterotransplantation into SCID mice and a comparison of the immunophenotypes and genotypes of the transplanted tumors with the primary tumors is presented. These transplanted tumors expressed a different pattern of lymphoid markers than did EBV-associated lymphoblastoid tumors that develop in SCID
The SCID mouse provides a model system for studying the growth of posttransplant lymphomas in vivo and for identifying clonal malignant cells from immunocompromised patients.
MATERIALS AND METHODS
Case selection. Four hundred eighty-six patients who had received heart, heart-lung, or kidney transplants during the period of June 1983 through December 1992 and who wereobserved at Stanford University Hospital and Clinics or the Palo Alto Veteran's Hospital were the potential subjects ofthis study. Nineteen cases of lymphoma or lymphoproliferative disorder within this patient population during this period were identified by reviewing pathology records; immunophenotyping results were available on 15 of them. Four cases of lymphoma that expressed at least two of a set of T-cell-associated markers (CD3, CD4, CD8, CD43, CD45Ro) and did not express the B-cell-associated antigen CD20 were identified. In addition, one case of a lymphoproliferative disorder (that resolved after immunosuppression was reduced) was noted. Limited immunophenotyping of these cells demonstrated that they were CD20-, CD43+, CD45Ro+; genotyping was not performed. Ten cases expressed CD20 and/or CD22 and were considered to have a B-cell phenotype.
Murine antibodies to human CD2, CD3, CD4, CD5, CD7, CD8, CDIIc, CD 14, CD 15, CD 19, CD20, CD2 1, CD22, CD23, CD43, and h and K Ig light chains were obtained from Becton Dickinson (Sunnyvale, CA). Antibodies to the y6 and a@ chains of the T-cell receptor (TCR) were purchased from T Cell Sciences (Cambridge, MA). Anti-CD30 antibody was purchased from Dakopatts (Glostrup, Denmark). Texas-Red-labeled goat antimouse IgG (heavy + light) was purchased from Caltag (South San Francisco, CA). Antibodies to CD32, CD37, and CD56 were a gift from Dr Roger Warnke (Stanford University). Cell surface staining and flow cytometric analysis of lymphoid cells was performed as previously described.*"
Tissue samples were fixed in buffered 10% formalin and processed for paraffin embedding. Sections were stained with hematoxylin and eosin for routine light microscopic examination. Cytospin preparations of cell suspensions were airdried and stained with Wright-Giemsa. Immunophenotypic studies, performed on paraffin and/or frozen sections at the time of diagnosis according to a method previously described?' were reviewed. Additional immunohistochemical studies were performed using a similar biotin-streptavidin technique. Briefly, 5-pm thick paraffin sections were deparaffinized and rehydrated. Endogenous peroxidase in tissue sections was blocked with 3% H,Oz for 5 min-
Fliiorescence-activated cellsorter (FACS) analysis.
Immunohistochemistry.
utes, followed by washing in phosphate-buffered saline (PBS). Sections or cytospin preparations were incubated with monoclonal antibody to CD20 (L26. B-cell marker; Dako, Carpinteria, CA); CD43, a lymphoid marker usually present on T-cell NHL (Leu 22; Becton Dickinson, Mountain View, CA)28; or CD3029 (Ber H2, activated lymphoid cells, Reed-Sternberg cells; anaplastic large-cell lymphoma: Dako). Sections were sequentially incubated with appropriate dilutions of biotin-conjugated goat antimouse (Jackson Immunoresearch Laboratories, Inc, West Grove. PA) and horseradish peroxidase-conjugated streptavidin (Jackson Research Laboratories). Each incubation was followed by washing in PBS. The peroxidase reaction was developed with 3% diaminobenzidine and sections were lightly counterstained with methylene blue.
Extraction of DNA from lymphoma tissue and Southern blot analyses were performed as previously described.30 Briefly, lymphoma tissue was digested with proteinase K and extracted with phenol, and the DNA was precipitated with ethanol. Genomic DNA was digested with the appropriate restriction enzyme, electrophoresed in a 0.7% agarose gel, denatured, neutralized, transferred to a nylon membrane, and fixed by baking at 80°C. Membranes were prehybridized and hybridized with a solution of 6X SSC, 5x Denhardt's, I % sodium dodecyl sulfate (SDS), 0.1 mg/mL salmon sperm DNA, and 50% formamide at 42"C, or with 250 mmol/L NaPO,, pH 7.2,7% SDS at 65°C. Specific DNA sequences were detected by hybridization with '2P-laheled probes3' containing sequences of the Ig heavy chain Jh. h chain constant region, K chain constant region, a pool of TCR JB1 and JB2, the BamV fragment of the EBV genome, or the 5.2-kb EcoRI-BamHI fragment ofthe fused termini.'5332-34 After hybridization for 12 to 18 hours, the filters were washed in 2X SSC + 0.1% SDS or with 20 mmol/L NaPO,, pH 7.2, I % SDS at 65°C with constant agitation. Autoradiographs were developed after 1 to 3 days of exposure to Kodak X-ray film (Eastman Kodak, Rochester, NY). One, two, or three DNA fragments containing germline sequences of the Ig or TCR genes were detected after hybridization with the corresponding specific probe. The presence of rearranged Ig or TCR gene sequences was indicated by the appearance of new bands not observed after hybridization of probes to control DNA. The detection of EBV DNA sequences on histologic sections of tissue from case no. 2 was performed by in situ hybridization using an EBV termini probe and in situ hybridization," and was performed by Dr Lawrence Weiss (City of Hope Hospital, Duarte, CA).
Cytogenetics. Cytogenetic analysis was performed on tumorcell suspensions using standard cytogenetic methodology. In short, cultures were harvested with simultaneous hypotonic shock3' and mitotic arrest with colcemid (final concentration, 0.05 pg/mL) for 25 minutes at 3 7 T , followed by fixation with 3: I methanol/acetic acid fixative. Chromosome slide preparations were made by standard methodology and analyzed using the GTW-banding method.36 Karyotypes were described by the International System for Human Cytogenetic N~menclature.~' C-B I7 scid/scid mice were obtained from Leonard Shultz (Jackson Labs, Bar Harbor, ME) and maintained under specific pathogen-free conditions in the animal facility of the Division of Radiobiology. Pleural fluid from the patient and lymphoma cell suspensions were injected into the peritoneal cavities ofSCID mice, Some SCID mice were immunosuppressed before transplantation of lymphoma cells by treatment with 1.75 C y whole body radiation."
Ascites cells ( 5 X lo6) from an SCID mouse bearing an intraperitoneal tumor resulting from a heterotransplanted lymphoma were put into culture in vitro in 20 mL of Iscove's media containing 15% vol/vol heat-inactivated fetal calf serum (FCS) in a humidified atmosphere containing 5% Genotypic analysis.
Transplantation of human lymphoma in SCID mice.
In vitro cultivation of'l.vmphoma cells.
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C02. The cells were passed every S to 7 days by transferring an aliquot into fresh Iscove's media containing 10% vol/vol FCS. The LHS21/4 cells were derived from the third serial passage of the primary tumor, LH52 1, in SCID mice, and had a doubling time of 48 hours, a cloning efficiency of 16% when diluted cell suspensions were plated into 96-well microtiter plates, and a cloning efficiency of 7% when individual CD30+ cells were sorted by FACS into separate culture dishes. The LK4 18/4B cells were derived form the third serial passage of the primary tumor, LK418, in SCID-hu mice.
RESULTS
Case history no. 1 . A 56-year-old man received a heart transplant after the diagnosis of congestive heart failure secondary to mitral valve prolapse. His immunosuppression consisted of cyclosporin A, azothioprim, and prednisone. Two years after his transplant he was noted to have enlarging right lower lobe lung nodules on his chest X-ray. A lobectomy showed two nodules, with the larger containing a tumor marked by necrosis and the presence of immunoblastic cells and the smaller nodule containing a diffuse infiltrate of atypical lymphoid cells. Immunophenotyping of the tumors showed the expression of T-cell markers CD2, 3, 8, 43 , and 45Ro and the absence of B-cell markers CD20 and 37 and X and K Ig ( Table 1) . Genotyping of the smaller nodule showed the absence of Ig gene rearrangements (not shown), the presence of a clonal TCR fl gene rearrangement, and a clonal population of cells containing EBV DNA (using a terminal repeat probe that indicates the unique site at which the circular EBV DNA genome was linearized and inserted into the tumor cell genome) (Fig 1) . Complete staging, including computer tomography (CT) scans and bone marrow biopsy, failed to show any other evidence ofdisease. Azothioprim was discontinued with the development of mild acute rejection on right ventricular biopsy. Azothioprim was reinstituted and new pulmonary nodules appeared on his chest X-ray 4 years after his transplant. Repeat biopsy showed atypical lymphoid cells having similar histology and an identical genotype compared with those of the previously excised T-cell lymphoma (Fig 1) . He received two cycles of chemotherapy consisting of VP-16 (epitoposide), procarbazine, and cyclophosphamide, followed by 4,000 rad external beam radiation to his right upper lobe. He remains free of lymphoma 6 years after his heart transplant and 2 years postchemotherapy.
A 5-year-old boy received a heart transplant after a diagnosis of restrictive cardiomyopathy. His immunosuppressive regime consisted of cyclosporin A, azothioprim, and prednisone. At 11 years of age he developed a lymphoproliferative disorder with a splenic mass. Splenectomy showed a large-cell lymphoma that expressed T-cell markers and lacked B-cell markers (Table 1) . Only paraffin-embedded tissue was available for immunohistochemical studies; therefore, the expression of only a limited number of T-cell and B-cell markers could be evaluated. Southern blots for Ig and TCR rearrangements were performed and showed the presence of a clonal rearrangement of the TCR fl gene, without evidence for rearranged Ig genes. The EBV DNA sequences were detected in lymphoma cells by an in situ technique using paraffin-embedded tissue, under conditions in which the morphology ofthe lymphoma cells was well preserved. In situ hybridization showed the presence of EBV DNA sequences in the lymphoma cells (not shown). His immunosuppressive drugs were reduced and he experienced an episode of severe acute rejection and died.
A 53-year-old man with a diagnosis of idiopathic glomerulonephritis received a cadaveric kidney allograft. He subsequently received a stable regime of oral immunosuppressive drugs consisting of cyclosporin A Case history no. 2. Case history no. 3. (Fig 2. middle panel) . Thoracentesis showed the presence of a large-cell lymphoma (designated herein as LH52 1) that was cytologically distinct from KS and expressed the lymphoid antigen CD30 (Fig 3  A and B) . Immunophenotyping showed the expression of CD4 and the absence of B-cell markers: genotyping demonstrated a clonal Ig heavy chain rearrangement, and the absence of EBV DNA sequences in the cells from the pleural effusion (Table I) He received six cycles of combination chemotherapy (VP-16, cyclophosphamide. and prednisone) with a resolution of the pleural effusion. He remains alive with a persistent radiographic abnormality on his chest x-ray (pleural thickening) without clinical or other radiographic evidence for active lymphoma.
An 18-year-old man received a heart transplant after a diagnosis of dilated cardiomyopathy. At 25 years of age, 7 years after his transplant, and while receiving cyclosporin A and prednisone. he presented with melena and a gastric mass below the gastro-esophogeal junction. Esophogogastrectomy showed the presence of a 6 X 8 x I5 cm intermediate-grade diffuse large-cell lymphoma (Fig 3D) . lmmunophenotyping showed the expression of CD4 (Fig 3E) and the absence of B-cell markers CD19, CD20, CD54RA. and surface Ig: genotyping showed clonal Ig heavy chain and K chain rearrangements and the presence of EBV DNA sequences (Table I) . His medical history included several episodes of mild graft rejection and an EBV infection 5 years earlier that led to mononucleosis and herpes meningitis that was treated with acyclovir. He began radiation therapy to regional lymph nodes: however, his disease progressed with lymphoma involving his skin. dura, spleen. and diffuse adenopathy. pressed the T-cell-associated markers CD43 and CD45R0, and lacked expression of CD20 and CD45RA. Tissue from case no. 3 and case no. 4 showed an unusual pattem of lymphoid markers, characterized by the expression of the T -c e l l -d a t e d markers CD4 (Fig 3E) and CD43 and the absence of surface Ig or TCR ( Table 1) . In addition, case no.
3 was noted to express high levels of CD30 (Fig 3B) , whereas case no. 4 expressed CD32 and CD37 (markers associated with some B-cell NHLs) and CD56, a marker assoCiated with natural killer (NK) cells ( The whereas LK4 18 failed to grow when injected intraperitoneally (IP) into SCID mice, but formed tumors after injection into the thymus xenografts in SCID-hu micez0 (Table 2) . In both cases, tumors, once established in SCID or SCID-hu mice, could be serially transplanted in SCID mice ( Table 2 ). The LH52 1 tumors that developed in SCID mice after IP injection had the histologic appearance of a large-cell lymphoma (Fig 3C) , and grew aggressively, involving mesenteric and intrathoracic lymph nodes, liver and spleen, and the abdominal wall musculature. Tumor-bearing mice developed ascites that contained more than 5 X lo6 lymphoma cells/mL. LK4 18 tumors ( Fig 3F) were more localized, arising from and completely replacing the left kidney, where the cell suspension had been injected into a human thymus xenograft, but failed to involve murine host mesenteric or intrathoracic lymph nodes or invade other abdominal organs. Once established as a tumor in SCID-hu mice, LK4 18 cells could be serially transplanted after IP injection into SCID mice (Table 2 ) and gave rise to localized tumors without invasion of murine host mesenteric lymph nodes or abdominal organs. The histologic appearance of both transplanted tumors was that of large-cell lymphomas (Fig 3C  and F) .
Flow cytometric analysis of the primary and transplanted lymphomas. The transplanted tumors that developed
from LH52 1 showed identical patterns of lymphoid antigen expression when compared with the primary tumor by flow cytometric analysis (Fig 4) . The patient's pleural fluid showed the presence of both CD3+ and CD3-populations, corresponding to the patient's normal peripheral T cells and tumor cells, respectively (Fig 4A) . The CD3+ cells had the scatter profile of small lymphocytes and expressed CD43 and low to absent amounts of CD30 (Fig 4B and C) . The CD3+ cells could be distinguished as CD4+8-and CD4-8' subpopulations whose relative proportions were similar to what is usually found in peripheral blood (Fig 4D) . The CD3-cells in the pleural fluid were larger, had a higher side scatter by flow cytometry (a measure of cytoplasmic granularity) than did PBL and expressed a high level of both CD30 and CD43 (Fig 4E and F) . They had high background autofluorescence in the fluorescein channels and did not express CD8, but did express CD4 at levels slightly lower than what was seen in the CD3+4+8-population from the pleural fluid (Fig 4G) . The CD3-cells in the pleural fluid did not express the B-cell markers CD19, 20, 21, and 23, IgM, and X or K light chain (not shown). The tumors that developed in SCID mice were CD3- (Fig 4H) and had an identical scatter profile (Fig 41) and pattern of CD4, CD30, and CD43 expression (Fig 4J) and absence of B-cell, other T-cell, and myelomonocytic/NK marker expression as the large CD3-cells from the pleural fluid (Fig 4K shows of the other lymphoid antigen was the same as shown for LH521 in Table 1 ).
Transplantation of LK4 18 cells into the thymic xenografts in SCID-hu mice resulted in the growth of two type of tumors, ie, those with an identical immunophenotype as the primary tumor as well as lymphomas whose characteristics were more typical of EBV-transformed lymphoblastoid cells. The primary tumor lacked expression of the pan B-cell markers CD19 and CD23 (Fig 5A) and surface Ig (Fig 5C) . The primary tumor expressed the T-cell markers CD4 ( Fig  5B) and CD43 (not shown), but not CD3 (Fig 5B) , TCR, or CD8 (not shown). One of the tumors that developed in an SCID-hu mouse, LK4 18/2A, expressed CD I9 and CD23 in a pattern typical of EBV+ lymphoblastoid cells (Fig 5D) , lacked CD4 expression (Fig 5E) , and contained small numbers of both A+ and K+ cells (Fig 5F) . Another transplanted tumor, LK4 18/2B, had an identical immunophenotype as the primary tumor (Table 1) ; in particular, it did not express CD19/CD23 or surface Ig (Fig 5G and I) , but did express CD4 (Fig 5H) Genotypic analysis of the primary lymphomas and the lymphomas that grew in SCID and SCID-hu mice. Southern blot analysis of Ig heavy chain gene structure of LH52 1 and the tumors that developed in SCID mice showed identical clonal rearrangements (Fig 6A, upper band) . The K chain gene had been deleted in the tumors that developed in SCID mice (Fig 6B, lanes 1 and Z) , whereas the X gene and TCR @ gene were in the germline configuration in the primary tumor sample as well as in the transplanted tumors (Fig 6C  and E) . Both the cells of the pleural fluid and the transplanted tumors lacked detectable EBV DNA sequences ( Fig  6D) .
Southern blot analysis of the primary tumor, LK4 18, showed a clonal Ig heavy chain rearrangement, a clonal X chain gene rearrangement, and germline K gene structure (Fig 7A, B, and C, lane 1) . One of the tumors that grew in SCID-hu mice, LK4 18/2A, a tumor that expressed a pattern of lymphoid markers typical of EBV-transformed lympho- blastoid cells (Fig 5D) , had different Ig heavy chain rearrangements and K gene structure compared with the primary tumor (Fig 7, lane 2) . In contrast, LK418/2B, the transplanted tumor with the CD4' immunophenotype ( Fig  5H) , had a genotype identical to that of the primary tumor (Fig 7, lane 3) . Both the primary tumor and two of the tumors that developed in SCID-hu mice contained EBV DNA sequences (Fig 7D) . Both the primary and transplanted tumors had germline TCR p gene structures ( Fig   7E) .
Cytogenetics of the primary and transplanted lymphomas showed shared chromosomal translocations. Cytogenetic analysis of the primary tumor from case no. 3, LH521, showed an abnormal human karyotype, as documented in Table 3 . The tumors that developed after serial transplantation in SCID mice showed multiple karyotypic abnormalities, and were clonally related because they shared common chromosomal rearrangements. These rearrangements were a translocation between chromosomes no. 1 and 16 [t( 1; 16) (p36;q22)], an abnormal chromosome no. 7 derived from an undetermined rearrangement [der(7)t(7;?)(p22;?)], an abnormal chromosome no. 12 derived from an undetermined rearrangement [der( 12)t( 12;?)(q24;?)], and an abnormal chromosome no. 15 derived from a translocation with a copy of the derivative chromosome no. 12 [der(l5)t (12;15)(ql l;q13)t( 12;?)(q24; (Table 2 ). An ascites that developed after two passages ofthe LK4 18 tumor in SCID-hu mice gave rise to a cell line, LK4 I8/4B, with the same immunophenotype as the primary tumor.
DISCUSSION
This report describes 4 cases of posttransplant lymphoma and 1 case of a lymphoproliferative disorder that expressed surface T-cell-associated markers and lacked the expression of surface Ig, CD20, or CD45Ra, B-cell markers commonly associated with NHL. These five cases comprise 26% of the ". Fig 5D) and lacked expression of CD4 (Fig 5E) . Lane 3 contains LK418/2B, the tumor that expressed CD4 (Fig 5H) . DNAs were analyzed for the presence of lg and TCR gene rearrangements as per the legend for pression. Richel et have reported a case of CD8+ EBV+ immunoblastic lymphoma that developed in a patient with angio-immunoblastic lymphadenopathy dysproteinemia (AILD). A 20% incidence of peripheral T cells containing clonal EBV DNA sequences has been reported in a series from Taiwan, an area where EBV-associated nasopharyngeal carcinoma is endemi~.~' This is the first report that we are aware of showing the presence of EBV DNA sequences in posttransplant T-cell NHL. The significance of the current report is that, in a small series from a single institution in patients who received cyclosporin A-based immunosuppression, the prevalence of lymphomas with a predominantly T-cell phenotype was 26%, with one-half of these cases showing clonal TCR gene rearrangements as well as expression of T-cell markers. This suggests that T cells, or lymphoid cells that retain the capacity to express T-cell-associated markers during differentiation, are potential targets for transformation in immunosuppressed individuals.
The primary and transplanted tumors from cases no. 3 and 4 studied in detail and described herein as LH52 1 and LK4 1 8 expressed the T-cell-associated markers CD4 and CD43, but contained clonal Ig gene rearrangements and TCR p genes in the germline configuration. In addition, LK4 18 expressed two surface markers associated with, but not restricted to, B cells: CD32, a marker associated with normal B cells, B-cell NHL, monocytes, granulocytes, and platelets4*; and CD37, a marker associated with most mature B cells, B-cell NHL, 10% of normal peripheral T cell, and 15% of T-cell malignan~ies.~~ LH52 I can be described as biphenotypic on the basis of the expression of T-cell surface markers, the absence of B-cell-associated markers, and an Ig gene rearrangement restricted to the B-cell lineage; LK418 could be described as biphenotypic on the basis of expression of both T-cell-and B-cell-associated markers. Biphenotypic lymphomas have been previously described as a heterogeneous group of neoplasms that express both T-cell-and B-cell-associated surface markers and as lymphoid neoplasms that have both Ig and TCR gene rearrangem e n t~.~~,~'
Compared with other reported cases of posttransplant lymphoma, case no. 3 was unusual for the absence of EBV DNA sequences in the primary tumor (Fig 6) . The history of diabetes mellitus and KS antedating the kidney transplant suggests that this patient may have had an underlying immunodeficiency in addition to his transplant-related immunosuppression. The posttransplant lymphomas that have been carefully studied generally contain EBV DNA, as do most cases of lymphoma that develop in patients with severe, intrinsic imm~nodeficiencies.'~ A single case of clonal, Bcell NHL that lacked EBV DNA sequences has been reported in a child with severe combined immunodeficiency." The remission of the lymphoma described in case no. 3 after the cessation of cyclosporin A (Fig 2) is consistent with the reported experience of other patients with posttransplant lymphomas, 30% to 60% of whom achieve durable remissions of their lymphomas after a reduction in immunosuppressive the rap^.^^.^^ The clonality of the tumor by genotyping and cytogenetics and the tumorigenicity of the LH52 1 lymphoma cells in SCID mice show that the pleural effusion that developed in this patient was truly malignant. Although the LH521 lymphoma cells from case no. 3 expressed CD30, a marker of activated lymphoid cells that is associated with Hodgkin's di~ease'~,'~ and a subset of anaplastic large-cell NHL,56 the clinical presentation of this patient (Fig 2) , the histologic appearance of his tumor cells, their expression of the T-cell-associated markers CD4 and Transplantation of the primary tumor, LK4 18, from case no. 4 yielded four tumors (Table 2) , two ofwhich were characterized by immunophenotyping and genotyping (Figs 5  and 7) . One of these tumors, LK418/2A, had a histology and immunophenotype typical of the tumors that developed from EBV-transformed lymphoblastoid peripheral B cells (Fig 5C, E, and F) and showed a different pattern of gene rearrangements compared with that of the clonal population of tumor cells in the patient's pleural effusion (Fig 7) . The second tumor characterized, LK4 18/2B, had an identical immunophenotype (Fig 5G, H , and I) and genotype (Fig   7) as the primary tumor. Both LK4 18/2A and LK4 18/2B possessed EBV DNA sequences (Fig 7) . We probed a Southem blot containing DNA from LK4 18/2A and LK4 18/2B for DNA sequences of the EBV terminal repeat. Unfortunately, no hybridization signals were detected due to the loss or degradation of the tumor DNA that had been previously bound to the nylon filter, and additional DNA from LK4 18/2A was not available for study. Although the presence of different clonal Ig rearrangements in LK4 18/2A and LK4 18/2B does not preclude that they were both derived from a common cell transformed by EBV before the rearrangement ofthe Ig gene, it is more likely that their transformation by EBV occurred after Ig gene rearrangements, because the expression of the EBV receptor, CD2 l, occurs after Ig gene rearrangement at the pre-B-cell stage in B-cell ~ntogeny.~' The primary tumor, LK418, was a homogeneous population, as assessed by FACS and Southem blot, and identical to the second tumor (LK4 18/2B) that grew in an SCID-hu mouse. The growth of another clone of EBVtransformed lymphoblastoid cells (LK4 18/2A) in an SCIDhu mouse after transplantation of the primary tumor confirms the unique sensitivity of SCID mice to the growth of EBV-transformed B cells, even to the extent that clonal, malignant lymphomas cells are outgrown by rare (4% of the original pleural effusion) B cells transformed by EBV.*O These data show that SCID mice may provide a model system in which to identify clonogenic malignant cells from immunosuppressed individuals, and illustrates that factors other than EBV can lead to transformation in the setting of immunodeficiency. Characterization of the events that lead to transformation in the setting of immunodeficiency will be important given the rising incidence of AIDS-related lymphomas6 and the increasing use of allogeneic organ transplantation and concomitant immunosuppression.
